Silencing of CSF2 expression in LN18 and U87 glioma cells did not significantly affect cell proliferation and survival, as demonstrated by BrdU incorporation (Fig. 2e, g) and MTT metabolism tests (Fig. 2f, h), respectively. This evidence concerns the gene CSF2 and central nervous system cancer.